SCHEMBL7797529

SCHEMBL7797529

CCOC(=O)C(Br)Cc1ccccc1OCCn1c(C)nc2ccccc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF4EBP1 Q13541 1/20 0.49
TSHR P16473 3/20 0.47
ATM Q13315 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HTR1A P08908 1/20 0.46
HTR7 P34969 1/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
GFER P55789 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5935688 0.85 GFER (0.49) EIF4EBP1TSHRATMMEN1KMT2A
SCHEMBL6858499 0.80 EIF4EBP1 (0.49) EIF4EBP1TSHRATMMEN1KMT2A
SCHEMBL6858494 0.76 EIF4EBP1 (0.49) EIF4EBP1TSHRATMMEN1KMT2A
SCHEMBL5935666 0.76 MAPT (0.48) TSHRATMMAPTALDH1A1SMN1; SMN2
SCHEMBL3829770 0.76 TSHR (0.64) EIF4EBP1TSHRATMMEN1KMT2A
SCHEMBL6555761 0.75 EIF4EBP1 (0.52) EIF4EBP1TSHRMEN1KMT2AHTR1A
SCHEMBL6555846 0.75 PPARA (0.60) EIF4EBP1TSHRMEN1KMT2AMAPT
SCHEMBL5807356 0.74 TSHR (0.48) EIF4EBP1TSHRATMMEN1KMT2A
SCHEMBL6858495 0.74 EIF4EBP1 (0.49) EIF4EBP1TSHRMEN1KMT2AHTR1A
SCHEMBL6556047 0.74 PPARG (0.52) EIF4EBP1TSHRATMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010031759-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031759-A1 Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases IAPP, GPR119, CYP11B1 EIF4EBP1 2495/4885TSHR 2420/4885ATM 2998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.